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Abstract 31 
Surgical attenuation of a congenital portosystemic shunts (CPSS) results in 32 
increased portal vein perfusion, liver growth and clinical improvement. Portal 33 
lipopolysaccharide (LPS) is implicated in liver regeneration via toll-like receptor 34 
(TLR) 4 mediated cytokine activation. The aim of this study was to investigate factors 35 
associated with LPS in dogs with CPSS.  36 
 37 
Plasma LPS concentrations were measured in the peripheral and portal blood 38 
using a limulus amoebocyte lysate (LAL) assay. LPS concentration was significantly 39 
greater in the portal blood compared to peripheral blood in dogs with CPSS (P = 40 
0.046) and control dogs (P = 0.002). LPS concentrations in the peripheral (P = 0.012) 41 
and portal (P = 0.005) blood of dogs with CPSS were significantly greater than those 42 
for control dogs. The relative mRNA expression of cytokines and TLRs was 43 
measured in liver biopsies from dogs with CPSS using quantitative PCR. TLR4 44 
expression significantly increased following partial CPSS attenuation (P = 0.020). 45 
TLR4 expression was significantly greater in dogs that tolerated complete CPSS 46 
attenuation (P = 0.011) and those with good portal blood flow on pre-attenuation (P = 47 
0.004) and post-attenuation (P = 0.015) portovenography. Serum IL-6 concentration 48 
was measured using a canine specific ELISA and significantly increased 24 h 49 
following CPSS attenuation (P < 0.001).  50 
Portal LPS was increased in dogs with CPSS, consistent with decreased 51 
hepatic clearance. TLR4 mRNA expression was significantly associated with portal 52 
blood flow and increased following surgery. These findings support the concept that 53 
portal LPS delivery is important in the hepatic response to surgical attenuation. Serum 54 
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IL-6 significantly increases following surgery, consistent with LPS stimulation via 55 
TLR4, although this increase might be non-specific.  56 
 57 
Keywords: Lipopolysaccharide; Toll like receptor 4; IL-6; Liver; Dog; congenital 58 
portosystemic shunts 59 
60 
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Introduction 61 
A congenital portosystemic shunt (CPSS) is an abnormal vessel connecting 62 
the portal venous system to the systemic venous system (Payne et al., 1990). A CPSS 63 
allows blood from the splanchnic viscera to bypass the liver, resulting in portal vein 64 
hypoperfusion and hence liver hypoplasia and hepatic insufficiency. Surgical CPSS 65 
attenuation is recommended to restore normal portal blood flow. Successful CPSS 66 
attenuation results in resolution of clinical signs, improvements in hepatic function 67 
and portal perfusion and increased liver volume (Hunt and Hughes, 1999; Kummeling 68 
et al., 2010; Lee et al., 2006; Stieger et al., 2007). These findings suggest that the 69 
return of normal hepatic size and function is achieved by liver regeneration. We have 70 
previously shown that markers of hepatocyte replication are associated with the 71 
degree of liver development and the response to surgery in dogs with CPSS, 72 
supporting a role for hepatic regeneration (Tivers et al., 2014a).  73 
 74 
Hepatic portal blood flow contributes 80% of the afferent liver blood flow and 75 
is vital for normal liver regeneration in people, rodents and dogs (Mathie et al., 1979; 76 
Michalopoulos, 2007). In experimental partial hepatectomy (PH) in pigs and rats, 77 
removal of two thirds of the liver mass caused an effective increase in hepatic portal 78 
blood flow (Kahn et al., 1984; Rice et al., 1977). It is unclear whether liver 79 
regeneration is stimulated by the increase in blood flow or by increased delivery of 80 
hepatotrophic substances in the portal blood (Mortensen and Revhaug, 2011). This 81 
increase in portal blood flow relative to liver mass is similar to that observed 82 
following CPSS attenuation. Intuitively, the response to CPSS attenuation is likely to 83 
be governed by similar factors.  84 
 85 
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Lipopolysaccharide (LPS) or endotoxin is a component of the cell wall of 86 
Gram-negative bacteria and is released following bacterial death. Gram-negative 87 
bacteria are present in the small intestine and therefore LPS is absorbed from the gut 88 
and into the portal vein (Peterson et al., 1991; Howe et al., 1997). LPS has been 89 
shown to play a positive role in liver regeneration in rodent models (Cornell, 1985a, 90 
b, 1990; Gao et al., 1999). Kupffer cells are specialised hepatic macrophages that bind 91 
LPS entering the liver via the portal vein (Freudenberg et al., 1982). LPS acts on 92 
Kupffer cells by binding to toll-like receptor (TLR) 4 (Fenton and Golenbock, 1998). 93 
Kupffer cells produce IL-6 and tumour necrosis factor (TNF) α after stimulation with 94 
LPS in rodents and these cytokines are implicated in the early stages of liver 95 
regeneration (Carswell et al., 1975; Shirahama et al., 1988; Decker et al., 1989; Hori 96 
et al., 1989; Busam et al., 1990). Activation of the cytokine network via LPS 97 
stimulation of Kupffer cells has been suggested as the stimulus for liver regeneration 98 
(Fausto, 2006a). Therefore, it is possible that LPS contributes to triggering the hepatic 99 
response to CPSS attenuation. 100 
 101 
The aim of this study was to investigate whether factors involved in LPS 102 
metabolism are increased after surgical attenuation of canine CPSSs. The first aim 103 
was to measure the concentration of LPS in portal blood compared with peripheral 104 
blood in dogs with CPSS at the time of surgery and control dogs. The second aim was 105 
to measure the hepatic mRNA expression of inflammatory cytokines and TLRs in 106 
dogs with CPSS, before and after partial attenuation. The third aim was to measure 107 
the serum IL-6 concentration before and immediately after CPSS attenuation. The 108 
hypotheses tested were that plasma LPS concentration would be significantly greater 109 
in the portal blood compared with the peripheral blood and that gene expression and 110 
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IL-6 concentration would significantly change in response to surgical CPSS 111 
attenuation.  112 
 113 
Materials and methods 114 
Clinical management 115 
Dogs with CPSS were prospectively recruited between August 2007 and 116 
October 2011. The Ethics Committee of the Royal Veterinary College granted ethical 117 
approval (original approval on 4th June 2004 and updated 22nd October 2010, URN 118 
2010 1058) and owners gave full, informed consent. Dogs were treated surgically via 119 
suture attenuation of their CPSS as previously described (Lee et al., 2006). Dogs that 120 
did not tolerate complete attenuation, due to intra-operative portal hypertension, had 121 
partial suture attenuation. Dogs treated with partial attenuation had repeat surgery 122 
approximately 3 months post-operatively.  123 
 124 
Portovenography was performed before and after temporary complete CPSS 125 
attenuation at each surgery to assess the development of the intrahepatic portal 126 
vasculature as previously described (Lee et al., 2006). Grade was determined 127 
according to the number of generations of intrahepatic portal vessels that were visible 128 
on a scale of 1 - 4 (Lee et al., 2006). Portovenogram grades of 1 and 2 represented 129 
poor portal blood flow and portovenogram grades of 3 and 4 represented good portal 130 
blood flow (Tivers et al., 2014b). 131 
 132 
Healthy experimental Beagle dogs that had been humanely destroyed for 133 
reasons unrelated to hepatic disease were used as controls for all parts of the study. 134 
7 
 
Dogs undergoing exploratory laparotomy for reasons unrelated to CPSS were also 135 
included as controls for the measurement of serum IL-6 only.  136 
 137 
Plasma LPS concentration 138 
Paired residual blood samples were taken peri-operatively from the jugular 139 
vein and mesenteric vein of dogs with CPSS. Residual samples were available as a 140 
consequence of placing a jugular central venous catheter pre-operatively and a 141 
mesenteric catheter intra-operatively for the measurement of portal pressures and for 142 
mesenteric portovenography. Blood samples were taken from Beagle control dogs 143 
from the jugular vein immediately before and from the portal vein immediately 144 
following euthanasia.  Samples were collected into heparinised, glass, pyrogen free 145 
tubes (Associates of Cape Cod) and the plasma was separated and stored at -80 °C. 146 
 147 
A limulus amebocyte lysate (LAL) assay using pyrochrome chromogenic 148 
reagent, reconstituted with glucashield beta glucan inhibiting buffer (Associates of 149 
Cape Cod) was used to measure the plasma LPS concentration. Samples were heated 150 
at 75 °C for 10 min and diluted 1:200 with LAL reagent water (Associates of Cape 151 
Cod). Samples were analysed in triplicate using an ELx808 absorbance microplate 152 
reader (BioTek). Sample concentration was calculated from the standard curve using 153 
Gen5 V1.07.5 software (BioTek).   154 
 155 
qPCR Gene Expression 156 
For dogs with CPSS, at each surgery a liver biopsy was taken for routine 157 
diagnostic purposes and a portion was placed in RNAlater (Sigma-Aldrich) and stored 158 
according to manufacturer’s instructions. Liver tissue was taken from Beagle control 159 
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dogs immediately following euthanasia and stored in the same way. Routine 160 
histopathology was performed on sections stained with haematoxylin and eosin.  161 
 162 
RNA was extracted from approximately 20-30 mg of each hepatic sample 163 
using the GenElute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich). The tissue 164 
was homogenised in 500 µL Lysis Solution using a Mixer Mill MM 300 (Retsch). An 165 
in-solution DNase digestion was performed using the Ambion TURBO DNA-free Kit 166 
(Life Technologies) to remove any contaminating DNA. RNA quality and quantity 167 
was assessed by microfluidic capillary electrophoresis using the Agilent 2100 168 
Bioanalyser (Agilent Technologies). The median RNA integrity number was 8.3 169 
(range, 7.1-9.2). No samples had genomic DNA contamination. Two separate cDNA 170 
were synthesised from each RNA sample using a mixture of random hexamer and 171 
oligo (dT)15 primers (Promega) and IMProm-II reverse transcriptase enzyme 172 
(Promega). Where possible, the amount of RNA template for cDNA synthesis was 173 
standardised at 1 µg. The cDNA was diluted to a final volume of 100 µL with 174 
nuclease-free water and stored at -20 °C before further use. 175 
 176 
Relative hepatic expression of five genes related to hepatic LPS signalling (IL-177 
1β, IL-6, TNFα, TLR2 and TLR4) was measured using quantitative polymerase chain 178 
reaction (qPCR). Published canine specific primers for the genes of interest (Wang et 179 
al., 2007; House et al., 2008) and four liver specific reference genes, hydroxymethyl-180 
bilane synthase, ribosomal protein L13a, ribosomal protein L32 and ribosomal protein 181 
S18, were used (Peters et al., 2007; Table 1). 182 
  183 
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For quantification, each liver sample had two cDNA samples analysed in 184 
duplicate. Reactions were carried out in 25 µL volumes using a Bio-Rad CFX96 Real-185 
Time PCR Detection System thermocycler (Bio-Rad Laboratories). Each reaction 186 
consisted of 1 L cDNA as the template with Immobuffer (1 × concentration), Hi-187 
Spec Additive (1 × concentration), dNTP (final concentration 1 mM), magnesium 188 
chloride (final concentration 2.5mM for genes of interest, 4.5mM for reference 189 
genes), 1 unit Immolase DNA polymerase (Bioline) and EvaGreen dye (Biotium; 0.06 190 
× diluted 1:4 with nuclease-free water). Samples were incubated at 95 °C for 10 min 191 
followed by 40 cycles of denaturation at 94 °C for 30 s, annealing at 55 °C for 30 s 192 
and elongation at 72 °C for 10 s. An appropriate primer-dimer melting temperature 193 
for 1 s was programmed before fluorescence readings were taken at the end of each 194 
cycle. A melting curve analysis from 65 oC to 95 oC with a plate read every 0.5 oC 195 
was performed at the end of 40 cycles. Bio-Rad CFX Manager Software (Bio-Rad) 196 
was used for initial qPCR analysis.  197 
 198 
Analysis of raw real-time data was performed using GenEx professional 199 
version 4.4.2 software (Multid Analyses). Relative gene expression was quantified as 200 
previously described (Vandesompele et al., 2002). Quantification cycle (Cq) values 201 
were corrected using the calculated efficiencies for each primer set. Normalisation of 202 
each sample Cq for the genes of interest was performed relative to the geometric 203 
normalisation of the four reference genes. The relative expression of the mRNA of 204 
each gene of interest in each cDNA sample was then calculated using the normalised 205 
Cq of each sample relative to the average Cq of all of the samples. For each gene the 206 
following comparisons were made: CPSS compared to control; partial attenuation 207 
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compared to complete attenuation; before and after partial attenuation (paired 208 
samples). 209 
 210 
Serum IL-6 concentration 211 
Blood samples were taken from both dogs with CPSS and control dogs that 212 
underwent exploratory laparotomy pre-operatively for diagnostic purposes and after 213 
surgery in dogs with CPSS for post-operative monitoring.  Where available, residual 214 
blood was used for the study. Residual blood samples were also taken immediately 215 
before euthanasia in Beagle control dogs. The serum was separated and stored at -80 216 
°C. 217 
 218 
A Quantikine Canine ELISA Kit (R and D Systems) was used to measure the 219 
serum concentration of IL-6 (Song et al., 2012). Samples were analysed in duplicate 220 
using an ELx808 absorbance microplate reader (BioTek). Sample concentration was 221 
calculated from the standard curve using Gen5 V1.07.5 software (BioTek). 222 
 223 
Statistical analysis 224 
Analysis was performed using PASW Statistics 18.0.0 statistical software 225 
package (Education SPSS, IBM). Continuous data were visually assessed for 226 
normality.  Median and range were reported for skewed data, which was compared 227 
with the Mann Whitney U test or the Wilcoxon signed-ranks test as appropriate. 228 
Repeated measures were compared with the Friedman’s two-way analysis of variance 229 
by ranks with pair-wise comparison. The LPS concentration and qPCR data was 230 
transformed to normal distribution (square root or logarithm). The data was then 231 
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compared with an independent t test or paired sample t test. Significance was set at 232 
the 5% level (P ≤ 0.05).  233 
 234 
Results 235 
Plasma LPS concentration 236 
Paired peripheral and portal plasma samples from 13 dogs with CPSS were 237 
included. The following breeds were included: Bichon Frise (n=2), Labrador (n=2), 238 
Border terrier (n=1), Cavalier King Charles spaniel (n=1), Crossbreed (n=1), Dogue 239 
de Bordeaux (n=1), German shepherd dog (n=1), Miniature Schnauzer (n=1), 240 
Springer spaniel (n=1), West Highland white terrier (n=1), Yorkshire terrier (n=1). 241 
The median age was 295 days (range, 125-1835 days). Nine dogs (69.2%) had an 242 
extrahepatic CPSS and four (30.8%) had an intrahepatic CPSS.  243 
 244 
Paired peripheral and portal plasma samples from nine healthy Beagles were 245 
included as control dogs. The median age was 1136 days (range, 497-1660 days), 246 
which was significantly greater than dogs with CPSS (P = 0.036). 247 
 248 
For dogs with CPSS, the median LPS concentration in the portal blood was 249 
0.453 endotoxin units (EU)/mL (range, 0.117-1.418 EU/mL), which was significantly 250 
greater than that in the peripheral blood (0.239 EU/mL; range, 0.056-1.410 EU/mL; P 251 
= 0.046; Fig. 1). For Beagle control dogs, the median LPS concentration in the portal 252 
blood was 0.184 EU/mL (range, 0.126-0.565 EU/mL), which was significantly greater 253 
than that in the peripheral blood (0.131 EU/mL; range, 0.061-0.187 EU/mL; P = 254 
0.002; Fig. 1). The LPS concentrations in the peripheral blood (P = 0.012) and portal 255 
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blood (P = 0.005) of dogs with CPSS were both significantly greater than for Beagle 256 
control dogs (Fig. 1).  257 
 258 
 259 
qPCR gene expression 260 
Liver samples obtained at the first surgery were available from 49 dogs. The 261 
following breeds were included: Yorkshire terrier (n=7), Crossbreed (n=6), Labrador 262 
(n=5), Miniature Schnauzer (n=5), West Highland white terrier (n=5), Cocker spaniel 263 
(n=4), Jack Russell terrier (n=3), Bichon Frise (n=2), Golden retriever (n=2), Lhasa 264 
Apso (n=2), Pug (n=2), Chihuahua (n=1), Hovawart (n=1), Irish Setter (n=1), Norfolk 265 
terrier (n=1), Old English sheepdog (n=1), Staffordshire bull terrier (n=1). The 266 
median age was 275 days (range, 97-4374 days). Thirty-eight (77.6%) dogs had an 267 
extrahepatic CPSS and 11 (22.4%) had an intrahepatic CPSS. Of the 49 dogs that had 268 
surgery, 24 (49%) had complete attenuation and 25 (51%) had partial attenuation. The 269 
25 dogs that had partial attenuation had repeat surgery a median of 110 days post-270 
operatively (range, 69-358 days). At the time of this repeat surgery, liver samples 271 
from these 25 dogs were obtained for a second analysis, enabling comparison of 272 
results with those from the first liver samples. At second surgery, 20 dogs tolerated 273 
complete CPSS attenuation, three dogs had progressed to complete shunt occlusion 274 
spontaneously (no flow on portovenography), and two dogs had developed multiple 275 
acquired shunts. The liver of all dogs with CPSS at first and second surgery showed 276 
characteristic changes consistent with portal hypoperfusion. No additional pathology 277 
was noted. Liver samples were acquired from seven Beagle control dogs as controls. 278 
The median age of control dogs was 628 days (range, 515-1544 days), which was 279 
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significantly older than for dogs with CPSS (P = 0.036). The liver of all control dogs 280 
was histopathologically unremarkable. The results are summarised in Table 2. 281 
 282 
Relative mRNA expression of IL-1β (P = 0.016) and IL-6 (P = 0.002) were 283 
both significantly greater for dogs with CPSS than for Beagle control dogs (Fig. 2). 284 
Relative TLR4 mRNA expression was significantly greater in dogs with complete 285 
attenuation compared with those with partial attenuation (P = 0.011; Fig. 2). Relative 286 
TLR4 mRNA expression significantly increased following partial attenuation (P = 287 
0.020; Fig. 2). Relative TLR4 mRNA expression was also compared between dogs 288 
with poor portal blood flow and those with good portal blood flow on 289 
portovenography (further details below). Relative TLR4 mRNA expression was 290 
significantly greater in dogs with good portal blood flow compared to those with poor 291 
portal blood flow on both pre-attenuation (P = 0.004) and post-attenuation 292 
portovenograms (P = 0.015; Fig. 3, Table 3).  293 
 294 
No significant associations were demonstrated for the relative mRNA 295 
expression of TNFα or TLR2.  296 
 297 
Portovenogram grading 298 
Complete portovenograms were available for 47/49 dogs at first surgery and 299 
21/25 dogs at second surgery. Pre-attenuation and post-attenuation portovenogram 300 
grades at first surgery were significantly greater for dogs with complete attenuation 301 
compared with dogs with partial attenuation (P < 0.001 for each). For dogs treated 302 
with partial attenuation, there was a significant increase in both pre-temporary CPSS 303 
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attenuation portovenogram grade (P < 0.001) and post-temporary CPSS attenuation 304 
portovenogram grade  (P = 0.001) from first to second surgery (Table 4).  305 
 306 
Serum IL-6 concentration 307 
Serum samples taken before and at 24 and 48 h post-surgery from 22 dogs 308 
with CPSS were analysed. The following breeds were included: Yorkshire terrier 309 
(n=4), Norfolk terrier (n=3), West Highland white terrier (n=3), Jack Russell terrier 310 
(n=2), Miniature Schnauzer (n=2), Shih Tzu (n=2), British bulldog (n=1), Crossbreed 311 
(n=1), Golden retriever (n=1), Labrador (n=1), Miniature Dachshund (n=1), Shetland 312 
sheepdog (n=1). The median age was 334.5 days (range, 114-2282 days). Nineteen 313 
(86.4%) dogs had an extrahepatic CPSS and three (13.6%) had an intrahepatic CPSS. 314 
Twelve dogs (54.5%) had complete attenuation and 10 (45.5%) had partial 315 
attenuation.  316 
 317 
Serum samples from seven healthy Beagles and five dogs undergoing 318 
abdominal surgery were included as controls. The following breeds were included in 319 
the abdominal surgery controls: Crossbreed (n=2), Golden retriever (n=1), Labrador 320 
(n=1), Shar Pei (n=1). The dogs were undergoing abdominal surgery for the 321 
investigation or treatment of insulinoma, adrenal carcinoma, splenic carcinoma, 322 
phaeochromocytoma and extrahepatic biliary tract obstruction. The median age of 323 
control dogs was 925 days (range, 526-4204 days); they were significantly older than 324 
dogs with CPSS (P < 0.001).  325 
 326 
There was no significant difference in pre-operative IL-6 concentrations 327 
between dogs with CPSS (median, 0 pg/mL; range, 0-876.75 pg/mL) and control dogs 328 
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(median, 0 pg/mL; range, 0-40.66 pg/mL). The median IL-6 concentration at 24 h in 329 
dogs with CPSS was 34.461 pg/mL (range, 0-483.726 pg/mL) and at 48 h was 8.137 330 
pg/mL (range, 0-683.925 pg/mL; Fig. 4). In dogs with CPSS, there was a significant 331 
difference in the concentration of IL-6 at the different time points (P < 0.001). Pair-332 
wise comparison of this data set confirmed that IL-6 at 24 h post-surgery was 333 
significantly greater than pre-surgery (P < 0.001). 334 
 335 
Discussion 336 
We measured the LPS concentration in peripheral and portal blood samples 337 
from dogs with CPSS and healthy Beagle control dogs. In normal animals and 338 
humans, LPS from the gut is transported to the liver by the portal system and is 339 
cleared by the Kupffer cells (Bradfield, 1974; Zlydaszyk and Moon, 1976; Jacob et 340 
al., 1977). Therefore, LPS is routinely detected in the portal circulation, but only a 341 
small amount is found in peripheral venous blood (Prytz et al., 1976; Jacob et al., 342 
1977). Portal LPS concentrations are significantly greater than peripheral 343 
concentrations in both healthy humans and those with liver disease (Tachiyama et al., 344 
1988; Lumsden et al., 1988; Benten et al., 2011; Sanada et al., 2012). However, LPS 345 
is increased in both the peripheral and portal blood of humans with liver cirrhosis due 346 
to increased absorption from the gut and decreased hepatic clearance (Lumsden et al., 347 
1988; Tachiyama et al., 1988; Lin et al., 1995; Kaser et al., 2002). This increase is 348 
thought to be due to either the shunting of blood past the liver via multiple acquired 349 
shunts (MAS) or impaired LPS clearance due to liver pathology (Kaser et al., 2002).  350 
 351 
Our study demonstrated that portal LPS concentration was significantly 352 
greater than peripheral concentration in dogs with CPSS and Beagle control dogs. 353 
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Peripheral and portal LPS concentrations were also significantly greater in dogs with 354 
CPSS compared to Beagle control dogs. These findings are consistent with those in 355 
humans. It is unsurprising that LPS concentrations were significantly greater in dogs 356 
with CPSS, as hepatic clearance is reduced as a consequence of shunting, as in 357 
humans with MAS. However, in people with liver cirrhosis there is also increased 358 
absorption of LPS from the gut, which is presumably not the case in dogs with CPSS. 359 
Thus, the main reason for the increase in LPS is likely to be decreased hepatic 360 
clearance. A previous study measured LPS in the peripheral and portal blood of 10 361 
dogs with CPSS compared with five control dogs using an LAL assay (Peterson et al., 362 
1991). Contrary to our study, there were no significant differences in LPS 363 
concentrations between peripheral and portal samples or between CPSS and control 364 
dogs. The reason for this discrepancy could be due to differences in experimental 365 
methodology or to variables in the dogs studied. Another study measured LPS 366 
concentration in the portal vein, hepatic vein and caudal vena cava of 10 dogs with 367 
experimentally created MAS and six control dogs using an LAL assay (Howe et al., 368 
1997). In agreement with our study, LPS concentration was significantly greater in all 369 
vessels for dogs with MAS compared with control dogs.  370 
 371 
In our study, and in the two canine studies mentioned above, an LAL assay 372 
was used to measure plasma LPS concentration. The LAL assay has been commonly 373 
used to measure plasma LPS in people with liver disease (Jacob et al., 1977; Lumsden 374 
et al., 1988; Tachiyama et al., 1988; Lin et al., 1995; Benten et al., 2011). Many 375 
variables can affect assay results and there is considerable variation in methodology 376 
between studies, which can affect the sensitivity and reliability of the LAL assay 377 
(Novitsky, 1994; Hurley, 1995). The endotoxin activity assay (EAA) is a more recent 378 
17 
 
technique for measuring endotoxin and uses chemiluminescence of neutrophil activity 379 
(Romaschin et al., 1998; Marshall et al., 2002). It has been used in both humans and 380 
dogs and is considered to be more accurate than the LAL method (Marshall et al., 381 
2002; Kjelgaard-Hansen et al., 2008; Sanada et al., 2011). It is possible that inclusion 382 
of the EAA test in our methodology might have improved the reliability of our results, 383 
but this test was not available to us for logistical and financial reasons. 384 
 385 
Our findings demonstrated that LPS concentration was increased in the portal 386 
blood of dogs with CPSS, most likely due to decreased hepatic clearance, suggesting 387 
that reduced delivery of portal blood to the liver is accompanied by reduced LPS 388 
delivery to the liver. This is consistent with the concept that portal delivery of LPS to 389 
the liver is a potential trigger for the hepatic response to attenuation. Surgical CPSS 390 
attenuation increases portal blood flow and hence increases LPS delivery to the liver. 391 
Following CPSS attenuation, normalisation of LPS concentrations is expected due to 392 
increased hepatic clearance. However, follow-up samples were not available so this 393 
was not assessed.  394 
 395 
We have demonstrated that there was a significant increase in serum IL-6 at 396 
24 h following CPSS attenuation. IL-6 is a key mediator of the initial stages of 397 
hepatic regeneration and rapid increases in hepatic and serum IL-6 are observed 398 
following PH in rodents (Cressman et al., 1996; Sakamoto et al., 1999; Iwai et al., 399 
2001; Aldeguer et al., 2002). Increased portal blood flow results in stimulation of 400 
Kupffer cells and release of IL-6, an initiator of regeneration (Decker, 1990; Meijer et 401 
al., 2000; Abshagen et al., 2007; Riehle et al., 2008).  The increase in IL-6 in dogs 402 
with CPSS following attenuation could, at least in part, be due to increased hepatic 403 
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blood flow and IL-6 release as part of liver regeneration. However, there is another 404 
possible explanation for the increase in IL-6. Abdominal surgery in humans is 405 
associated with an inflammatory response, resulting in increased IL-6 in the 406 
peripheral and portal blood (Cruickshank et al., 1990; Di Padova et al., 1991; Baigrie 407 
et al., 1992; Glaser et al., 1995; Biffl et al., 1996; Kimura et al., 1998). Logically, the 408 
increase in serum IL-6 following CPSS surgery might also be due to surgical trauma. 409 
A control group of dogs undergoing laparotomy for reasons unrelated to CPSS 410 
attenuation with pre- and post-operative serum samples would have provided more 411 
information on the specificity of post-operative increase in IL-6.  412 
 413 
Significant post-operative increases in serum IL-6 are seen in humans 414 
undergoing PH for tumour resection and in individuals donating or receiving liver 415 
transplants (Kimura et al., 1998, 1999; Hu et al., 1999; Asakura et al., 2000; Chijiiwa 416 
et al., 2002; Slotwinski et al., 2002). One study demonstrated a significant increase in 417 
serum IL-6 at 24, 72 and 168 h post-hepatectomy for liver donation, but there was no 418 
significant increase post-hepatectomy for benign neoplasia (Slotwinski et al., 2002). 419 
The study concluded that in humans with normal livers, IL-6 increased following 420 
partial hepatectomy, consistent with hepatic regeneration. This is similar to the 421 
findings of our study, although IL-6 rapidly returned to normal, whereas it remained 422 
increased in people following hepatectomy. In other studies of abdominal surgery in 423 
people, IL-6 levels increase rapidly to peak at 4-48 h post-operatively, but can remain 424 
increased for 48-72 h (Di Padova et al., 1991; Baigrie et al., 1992; Biffl et al., 1996). 425 
The reason for these discrepancies is unclear, but could be related to differences in the 426 
nature of the surgery and therefore the hepatic response, species differences, 427 
differences in methodology and assay sensitivity. However, pre-existing liver disease 428 
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is associated with increased IL-6 and this could affect post-operative changes (Hu et 429 
al., 1999; Slotwinski et al., 2002). Similarly, dogs with liver disease have increased 430 
serum IL-6 concentrations compared with healthy dogs (Neumann et al., 2012). In a 431 
recent study, plasma IL-6 concentrations were increased in dogs with CPSS 432 
(Kilpatrick et al., 2014). Our study did not find a significant difference in serum IL-6 433 
concentrations between CPSS and control dogs. However, it is possible that 434 
differences in the populations and methodology could be responsible for this 435 
discrepancy. Additionally, our study had a relatively small number of control dogs, 436 
perhaps resulting in a type II statistical error.  437 
 438 
We measured the expression of IL-1β, IL-6 and TNFα mRNA in liver tissue. 439 
The expression of both IL-1β and IL-6 mRNA in liver tissue were significantly 440 
greater in dogs with CPSS compared to Beagle control dogs. IL-1β, IL-6 and TNFα 441 
are inflammatory cytokines that are released by Kupffer cells in response to 442 
stimulation by LPS (Shirahama et al., 1988; Decker et al., 1989; Busam et al., 1990). 443 
IL-6 and TNFα are initiators of regeneration and IL-1β inhibits regeneration (Boulton 444 
et al., 1997; Fausto et al., 2006b; Riehle et al., 2011). Therefore, it seems incongruous 445 
that both IL-6 and TNFα are increased in an underdeveloped CPSS liver. As 446 
mentioned above, abdominal surgery initiates an inflammatory response accompanied 447 
by increases in serum IL-6 and IL-1β; increases in IL-1β precede those for IL-6 448 
(Baigrie et al., 1992; Glaser et al., 1995; Kimura et al., 1998). It is possible that liver 449 
biopsy would result in similar increases in IL-1β and IL-6 in the traumatised tissue. 450 
Therefore, the increased cytokine expression in CPSS liver tissue could be due to 451 
acute release following surgical trauma. As control liver tissue was obtained post-452 
mortem, there might not have been similar increases in cytokine expression. 453 
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However, this potential explanation is conjecture and remains unproven. Several 454 
studies have shown that dogs with CPSS, and in particular those with hepatic 455 
encephalopathy, have evidence of generalised inflammation with increased serum IL-456 
6, plasma C-reactive protein (CRP) and systemic inflammatory response syndrome 457 
scores (Gow et al., 2012; Kilpatrick et al., 2014; Tivers et al., 2014c, 2015). It is 458 
possible that more generalised increases in IL-1β and IL-6 as a result of pre-existing 459 
inflammation could be responsible for the increased hepatic expression of these 460 
cytokines. It is also possible that differences in IL-1β and IL-6 between the CPSS and 461 
control dogs could have been due to differences in breed and age between the two 462 
groups. However, if this were the case, a physiological reason for this difference is 463 
unclear.  464 
 465 
We measured the hepatic mRNA expression of TLR2 and TLR4. TLR4 466 
mRNA expression was significantly increased in dogs with CPSS tolerating complete 467 
attenuation compared to those which tolerated only partial attenuation. Dogs with 468 
well-developed intrahepatic portal vasculature on portovenography had significantly 469 
increased TLR4 mRNA expression. Additionally, TLR4 mRNA expression 470 
significantly increased following partial attenuation.  In contrast, no significant 471 
differences were identified for TLR2.  This finding might be because TLR2 plays a 472 
major role in detection of Gram-positive bacteria, recognising components of the cell 473 
wall including peptidoglycan, lipoteichoic acid and lipoproteins (Yoshimura et al., 474 
1999).   Gram-positive bacteria are not the predominant component of typical gut 475 
flora. The absence of a significant difference in TLR2 mRNA expression in 476 
conjunction with a significant increase in TLR4 mRNA expression increases the 477 
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likelihood that these data reflect a specific interaction between gut flora pathogen-478 
associated molecular patterns and the hepatic response to CPSS attenuation. 479 
 480 
TLR4 is expressed by Kupffer cells and binds LPS, enabling circulatory 481 
clearance of LPS (Freudenberg et al., 1982; Fenton and Golenbock, 1998). LPS is 482 
very important for normal hepatic regeneration (Cornell, 1985a, b, 1990; Gao et al., 483 
1999). Kupffer cell release of IL-6 and TNFα in response to LPS is implicated in the 484 
initiation of hepatic regeneration (Fausto, 2006a). Increased expression of TLR4 485 
mRNA suggests increased LPS binding capacity in dogs with CPSS and good portal 486 
blood flow and in those able to tolerate complete attenuation. As partial attenuation 487 
increases portal blood flow, increased TLR4 mRNA is therefore consistent with 488 
increased LPS delivery. This provides further evidence that TLR4 and blood flow are 489 
important in the hepatic response to surgery.  These findings demonstrate that TLR4 490 
mRNA expression is linked with portal blood flow and in the response to surgical 491 
attenuation in dogs with CPSS. We have previously shown that the hepatic expression 492 
of hepatocyte growth factor (HGF) and methionine adenosyltransferase 2 A, which 493 
are both markers of hepatocyte replication, are significantly increased following 494 
partial CPSS attenuation (Tivers et al., 2014a). We have also shown that vascular 495 
endothelial growth factor receptor 2 (VEGFR2) is significantly associated with the 496 
degree of portal blood flow and significantly increases following partial CPSS 497 
attenuation (Tivers et al., 2014b). In addition, these studies also demonstrated that 498 
there were significant increases in HGF and VEGF immediately following CPSS 499 
surgery (Tivers et al., 2014a, b). These data suggest that both hepatic regeneration, in 500 
the form of hepatocyte replication and angiogenesis, are associated with CPSS 501 
attenuation. The findings of the current study are in broad agreement with these 502 
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findings and support the concept that activation of Kupffer cells via TLR4 binding of 503 
LPS could be involved in this process. Further work is needed to explore this concept. 504 
 505 
There are a number of limitations to the current study that must be taken into 506 
account. The number of dogs included in the study was relatively small, particularly 507 
for the measurement of plasma LPS and in the control groups for the other 508 
experiments. Larger group size might have allowed further statistically significant 509 
findings to be identified. Nevertheless, we were able to identify a number of findings 510 
that were both biologically relevant and statistically significant. In addition, the 511 
experimental Beagles used as control dogs were significantly older than the dogs with 512 
CPSS. Consequently, it is possible that the differences detected in LPS concentration 513 
and cytokine mRNA expression could have been related to breed or age rather than to 514 
CPSS.   515 
 516 
Conclusions 517 
Our results have demonstrated that portal LPS is increased in dogs with CPSS, 518 
consistent with decreased hepatic clearance due to shunting. In addition, hepatic 519 
TLR4 mRNA expression was significantly associated with portal blood flow and 520 
significantly increased following CPSS attenuation. This suggests that LPS binding 521 
capacity via TLR4 is linked to blood flow and the degree of portal development. This 522 
provides supporting evidence for the concept that LPS triggers liver regeneration via 523 
Kupffer cell binding and signalling following CPSS attenuation. Further 524 
investigations are warranted to explore this mechanism in more depth. 525 
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Table 1 858 
Table showing details of reference gene and gene of interest primer pairs for quantitative PCR. 859 
 860 
Gene Primer sequences PCR amplicon 
length (bp) 
Genbank accession 
number 
Primer sequence 
reference 
HMBS Forward: TCACCATCGGAGCCATCT 
Reverse: GTTCCCACCACGCTCTTCT 
112 XM546491 Peters et al., 2007 
RPL13A Forward: GCCGGAAGGTTGTAGTCGT 
Reverse: GGAGGAAGGCCAGGTAATTC 
87 AJ388525 Peters et al., 2007 
RPL32 Forward: TGGTTACAGGAGCAACAAGAAA 
Reverse: GCACATCAGCAGCACTTCA 
100 XM_848016 Peters et al., 2007 
RPS18 Forward: TGCTCATGTGGTATTGAGGAA 
Reverse: TCTTATACTGGCGTGGATTCTG 
116 XM_532106 Peters et al., 2007 
IL-1β Forward: TCTCCCACCAGCTCTGTAACAA 
Reverse: GCAGGGCTTCTTCAGCTTCTC 
80 Z70047 Wang et al., 2007 
IL-6 Forward: TCCTGGTGATGGCTACTGCTT 
Reverse: GACTATTTGAAGTGGCATCATCCTT 
78 U12234 Wang et al., 2007 
TNFα Forward: GAGCCGACGTGCCAATG 
Reverse: CAACCCATCTGACGGCACTA 
79 Z70046 Wang et al., 2007 
TLR2 Forward: AGTGGCCAGAAAAGCTGAAA  
Reverse: ATCCAGTTGCTCCTTCGAGA 
263 NM001005264 House et al., 2008 
TLR4 Forward: CAAAATCCCCAACAACATCC 
Reverse: TGGTTTAGGCCCTGATATGC 
171 NM001002950 House et al., 2008 
bp, base pairs; HMBS, hydroxymethyl-bilane synthase; RP, ribosomal protein; TNF, tumour necrosis factor; TLR, toll-like receptor   861 
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Table 2 862 
Relative mRNA expression of cytokines and toll-like receptors (normalised with respect to four liver specific reference genes) in liver biopsies 863 
from 49 dogs with congenital portosystemic shunts (CPSS) and seven Beagle control dogs. Results are presented as median and range.  864 
Gene Control compared to CPSS Complete attenuation compared to partial 
attenuation 
Before and after partial attenuation 
(n=25) 
Control a 
(n=7) 
CPSS 
(n=49) 
P  Partial 
(n=25) 
Complete 
(n=24) 
P  Before partial 
attenuation 
After partial 
attenuation 
P  
IL-1β 3.351 
(2.361-5.723) 
11.172 
(1.654-919.494) 
0.016b 7.817 
(1.654-197.141) 
11.849 
(2.826-919.494) 
0.052 7.817 
(1.654-197.141) 
8.981 
(1.975-169.281) 
0.800 
IL-6 2.569 
(1.288-3.463) 
9.473 
(1.581-332.589) 
0.002b 8.310 
(1.914-332.589) 
13.044 
(1.581-229.601) 
0.421 8.310 
(1.914-332.589) 
5.543 
(1.548-207.752) 
0.155 
TNFα 2.554 
(2.158-4.402) 
2.818 
(1.509-11.364) 
0.772 2.736 
(1.509-5.917) 
2.833 
(1.544-11.364) 
0.601 2.736 
(1.509-5.917) 
2.748 
(1.326-14.032) 
0.174 
TLR2 2.041 
(1.700-3.525) 
2.241 
(1.396-9.904) 
0.298 2.204 
(1.396-5.046) 
2.242 
(1.602-9.904) 
0.401 2.204 
(1.396-5.046) 
2.372 
(1.189-12.289) 
0.148 
TLR4 4.340 
(4.005-7.049) 
5.067 
(1.581-20.575) 
0.396 4.337 
(1.581-14.505) 
6.189 
(3.183-20.575) 
0.011b 4.337 
(1.581-14.505) 
6.065 
(1.627-11.617) 
0.020b 
IL, interleukin; TNF, tumour necrosis factor; TLR, toll-like receptor 865 
a Beagle dogs 866 
b Statistically significant value (P ≤ 0.05) 867 
  868 
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Table 3 869 
Relative mRNA expression of toll-like receptor 4 (TLR4), normalised with respect to four liver specific reference genes, in liver biopsies from 870 
47 dogs with congenital portosystemic shunts as related to portal blood flow on pre-attenuation and post-attenuation portovenogram, at first 871 
surgery. Results are presented as median and range.  872 
Gene Pre-attenuation portal blood flow Post-attenuation portal blood flow 
Poor 
(35 dogs) 
Good 
(12 dogs) 
P  Poor 
(12 dogs) 
Good 
(35 dogs) 
P  
TLR4 4.607 
(1.581-14.505) 
7.638 
(3.423-20.575) 
0.004a 4.271 
(1.581-8.060) 
5.513 
(2.188-20.575) 
0.01 a 
a Statistically significant value (P ≤ 0.05) 873 
 874 
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Table 4 875 
Portovenogram grade before and after temporary congenital portosystemic shunt 876 
attenuation in 21 dogs at first and second surgery. This group of dogs all had a partial 877 
attenuation at the first surgery. There was a significant increase in portovenogram 878 
grade for both pre-attenuation and post-attenuation from first to second surgery (P < 879 
0.001 and P = 0.001, respectively).  880 
 881 
Timing of assessment n (%) dogs for each portovenogram grade 
Grade 1 Grade 2 Grade 3 Grade 4 
1st Surgery Pre-attenuation 18 (85.7) 3 (14.3) 0 (0) 0 (0) 
1st Surgery Post-attenuation 0 (0) 12 (57.1) 9 (42.9) 0 (0) 
2nd Surgery Pre-attenuation 2 (9.5) 8 (38.1) 6 (28.6) 5 (23.8) 
2nd Surgery Post-attenuation 0 (0) 4 (19.0) 6 (28.6) 10 (52.4) 
  882 
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Figure legends 883 
 884 
Fig. 1. Measurement of lipopolysaccharide (LPS) concentration (endotoxin units 885 
[EU]/mL) in peripheral and portal plasma from 13 dogs with congenital portosystemic 886 
shunts (CPSS) and nine healthy Beagle control dogs using a limulus amebocyte lysate 887 
(LAL) assay. Statistical significance is highlighted with the corresponding P value. 888 
(A) Peripheral and portal LPS concentration in dogs with CPSS. (B) Peripheral and 889 
portal LPS concentrations in Beagle control dogs. (C) Peripheral LPS concentration in 890 
Beagle control dogs compared with dogs with CPSS. (D) Portal LPS concentration in 891 
Beagle control dogs compared with dogs with CPSS.  892 
 893 
Fig. 2. Relative cytokine and toll-like receptor mRNA expression (normalised with 894 
respect to four liver specific reference genes) in liver biopsies from 49 dogs with 895 
congenital portosystemic shunts (CPSS) and seven Beagle control dogs. The graphs 896 
show statistically significant findings for the five genes assessed. Statistical 897 
significance is highlighted with the corresponding P value. (A) Interleukin 1 beta (IL-898 
1β) mRNA expression in Beagle control dogs compared with dogs with CPSS. (B) 899 
Interleukin 6 (IL-6) mRNA expression in Beagle control dogs compared with dogs 900 
with CPSS. (C) Toll-like receptor 4 (TLR4) mRNA expression in dogs with CPSS 901 
tolerating a partial attenuation compared with those tolerating a complete attenuation. 902 
(D) TLR4 mRNA expression in dogs with CPSS at first surgery compared with 903 
second surgery. 904 
 905 
Fig. 3. Relative mRNA expression of toll-like receptor 4 (TLR4), normalised with 906 
respect to four liver specific reference genes, in liver biopsies from 47 dogs with 907 
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congenital portosystemic shunts (CPSS) as related to portal blood flow on pre-908 
attenuation and post-attenuation portovenogram. Portovenogram grades of 1 and 2 909 
were considered poor portal blood flow and portovenogram grades of 3 and 4 were 910 
considered good portal blood flow. Statistical significance is highlighted with the 911 
corresponding P value. (A) TLR4 mRNA expression in dogs with CPSS with poor 912 
portal blood flow compared with dogs with CPSS with good portal blood flow on pre-913 
attenuation portovenogram. (B) TLR4 mRNA expression in dogs with CPSS with 914 
poor portal blood flow compared with dogs with CPSS with good portal blood flow 915 
on post-attenuation portovenogram.  916 
 917 
 918 
Fig. 4. Serum interlukin 6 (IL-6) concentration in 22 dogs with congenital 919 
portosystemic shunts pre-surgery and at 24 and 48 h post-surgery. IL-6 concentration 920 
was measured using a canine IL-6 ELISA kit. There was a significant difference in 921 
the concentration of IL-6 at the different time points (P < 0.001). Pair-wise 922 
comparison of this data set confirmed that IL-6 at 24 h post-surgery was significantly 923 
greater than pre-surgery (P < 0.001). 924 
